LB Pharmaceuticals Inc. (LBRX)

LB Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	-29.43	-63.1	-6.28
Depreciation & Amortization	0	0.06	4.32
Share-Based Compensation	-	3.09	0.3
Other Operating Activities	-12.01	6.9	-10.43
Operating Cash Flow	-41.43	-53.05	-12.09
Capital Expenditures	-0.69	-0.77	-0.03
Change in Investments	-	24	-27.99
Investing Cash Flow	47.4	23.23	-28.01
Share Issuance / Repurchase	-	40.02	35
Debt Issued / Paid	-	-	0.73
Other Financing Activities	0.02	-1.71	-2.05
Financing Cash Flow	0.02	38.32	33.68
Net Cash Flow	5.99	8.5	-6.43
Free Cash Flow	-42.13	-53.82	-12.12

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).